Nicolas Hohmann

1.5k total citations
36 papers, 1.0k citations indexed

About

Nicolas Hohmann is a scholar working on Pharmacology, Oncology and Pharmacology. According to data from OpenAlex, Nicolas Hohmann has authored 36 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmacology, 12 papers in Oncology and 9 papers in Pharmacology. Recurrent topics in Nicolas Hohmann's work include Pharmacogenetics and Drug Metabolism (14 papers), Antibiotics Pharmacokinetics and Efficacy (8 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Nicolas Hohmann is often cited by papers focused on Pharmacogenetics and Drug Metabolism (14 papers), Antibiotics Pharmacokinetics and Efficacy (8 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Nicolas Hohmann collaborates with scholars based in Germany, United States and Italy. Nicolas Hohmann's co-authors include Gerd Mikus, Walter E. Haefeli, Jürgen Burhenne, Alexandra Carls, Antje Blank, David Czock, Alexander I. Alexandrov, Stephan Urban, Matthias Schwab and Mathias Haag and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Hepatology and Annals of Oncology.

In The Last Decade

Nicolas Hohmann

35 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicolas Hohmann Germany 16 279 272 254 185 163 36 1.0k
Scott Q. Siler United States 19 242 0.9× 262 1.0× 412 1.6× 275 1.5× 118 0.7× 30 1.4k
Marina Kacevska Australia 14 194 0.7× 384 1.4× 373 1.5× 364 2.0× 109 0.7× 14 1.2k
Ziad Abdel‐Razzak Lebanon 14 227 0.8× 348 1.3× 496 2.0× 305 1.6× 137 0.8× 25 1.2k
Imir G. Metushi United States 15 123 0.4× 240 0.9× 495 1.9× 232 1.3× 90 0.6× 29 1.0k
Terrilyn A. Richardson United States 11 174 0.6× 382 1.4× 415 1.6× 308 1.7× 53 0.3× 12 1.1k
Andreas Benesic Germany 17 253 0.9× 141 0.5× 449 1.8× 243 1.3× 287 1.8× 30 1.1k
Katsuyuki Fukuda Japan 24 277 1.0× 386 1.4× 492 1.9× 354 1.9× 51 0.3× 114 1.9k
Romi Ghose United States 19 137 0.5× 397 1.5× 297 1.2× 444 2.4× 54 0.3× 45 1.1k
Elton R. Kisanga Tanzania 12 203 0.7× 221 0.8× 222 0.9× 259 1.4× 39 0.2× 18 1.0k
PB Watkins United States 8 345 1.2× 341 1.3× 904 3.6× 141 0.8× 296 1.8× 10 1.2k

Countries citing papers authored by Nicolas Hohmann

Since Specialization
Citations

This map shows the geographic impact of Nicolas Hohmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Hohmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Hohmann more than expected).

Fields of papers citing papers by Nicolas Hohmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Hohmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Hohmann. The network helps show where Nicolas Hohmann may publish in the future.

Co-authorship network of co-authors of Nicolas Hohmann

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Hohmann. A scholar is included among the top collaborators of Nicolas Hohmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Hohmann. Nicolas Hohmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hohmann, Nicolas, et al.. (2024). Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin. Clinical and Translational Science. 17(8). e70007–e70007. 7 indexed citations
2.
Hohmann, Nicolas, Robin Michelet, Andreas D. Meid, et al.. (2022). Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion. Clinical Pharmacokinetics. 61(11). 1595–1607. 10 indexed citations
3.
Hohmann, Nicolas, Gerd Mikus, Walter E. Haefeli, et al.. (2019). A follow-up report on potential drug interactions with clementines: Two single case experiments show no effect on CYP3A-dependent midazolam clearance. European Journal of Pharmaceutical Sciences. 133. 54–58. 4 indexed citations
4.
Hohmann, Nicolas, Antje Blank, Jürgen Burhenne, et al.. (2019). Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. British Journal of Clinical Pharmacology. 85(10). 2310–2320. 13 indexed citations
5.
Raab, Marc S., Sheeba K. Thomas, Enrique M. Ocio, et al.. (2019). The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia. 33(12). 2924–2933. 52 indexed citations
6.
Hohmann, Nicolas, Antje Blank, Johanna Weiß, et al.. (2017). Autoinhibitory properties of the parent but not of the N‐oxide metabolite contribute to infusion rate‐dependent voriconazole pharmacokinetics. British Journal of Clinical Pharmacology. 83(9). 1954–1965. 19 indexed citations
7.
Schmitz-Winnenthal, Friedrich H., Nicolas Hohmann, Thomas Schmidt, et al.. (2017). A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. OncoImmunology. 7(4). e1303584–e1303584. 60 indexed citations
8.
9.
Hohmann, Nicolas, Walter E. Haefeli, & Gerd Mikus. (2016). CYP3A activity: towards dose adaptation to the individual. Expert Opinion on Drug Metabolism & Toxicology. 12(5). 479–497. 49 indexed citations
10.
Hohmann, Nicolas, Alexandra Carls, Jürgen Burhenne, et al.. (2016). Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. Clinical Pharmacokinetics. 55(12). 1535–1545. 59 indexed citations
11.
Blank, Antje, Christoph Markert, Nicolas Hohmann, et al.. (2016). First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. Journal of Hepatology. 65(3). 483–489. 166 indexed citations
12.
Hohmann, Nicolas, Raphael Reinhard, Sven Schnaidt, et al.. (2016). Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans. Journal of Antimicrobial Chemotherapy. 71(8). 2241–2247. 6 indexed citations
13.
Theile, Dirk, Nicolas Hohmann, Dominik Kiemel, et al.. (2016). Clementine juice has the potential for drug interactions – In vitro comparison with grapefruit and mandarin juice. European Journal of Pharmaceutical Sciences. 97. 247–256. 32 indexed citations
14.
Hohmann, Nicolas, et al.. (2015). St. John’s wort treatment in women bears risks beyond pharmacokinetic drug interactions. Archives of Toxicology. 90(4). 1013–1015. 3 indexed citations
15.
Hohmann, Nicolas, Walter E. Haefeli, & Gerd Mikus. (2015). Use of Microdose Phenotyping to Individualise Dosing of Patients. Clinical Pharmacokinetics. 54(9). 893–900. 16 indexed citations
16.
Hohmann, Nicolas, Gerd Mikus, & David Czock. (2014). Effects and Risks Associated with Novel Psychoactive Substances. Deutsches Ärzteblatt international. 111(9). 139–47. 70 indexed citations
17.
Schmitz-Winnenthal, Friedrich H., Lars Grenacher, Heinz Lubenau, et al.. (2013). VXM01, an oral T-cell vaccine targeting the tumor vasculature: Results from a randomized, controlled, first-in-man study in pancreatic cancer patients.. Journal of Clinical Oncology. 31(15_suppl). 3090–3090. 5 indexed citations
18.
Hohmann, Nicolas, et al.. (2013). A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions. Clinical Pharmacology & Therapeutics. 93(6). 564–571. 76 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott Q. Siler Breakdown of academic impact, for papers by Marina Kacevska Breakdown of academic impact, for papers by Ziad Abdel‐Razzak Breakdown of academic impact, for papers by Imir G. Metushi Breakdown of academic impact, for papers by Terrilyn A. Richardson Breakdown of academic impact, for papers by Andreas Benesic Breakdown of academic impact, for papers by Katsuyuki Fukuda Breakdown of academic impact, for papers by Romi Ghose Breakdown of academic impact, for papers by Elton R. Kisanga Breakdown of academic impact, for papers by PB Watkins
Rankless by CCL
2026